Free Trial
NASDAQ:XBIO

Xenetic Biosciences Q1 2025 Earnings Report

Xenetic Biosciences logo
$2.85 +0.16 (+5.91%)
As of 04/25/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Xenetic Biosciences EPS Results

Actual EPS
N/A
Consensus EPS
-$0.72
Beat/Miss
N/A
One Year Ago EPS
N/A

Xenetic Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.52 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Xenetic Biosciences Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Friday, May 9, 2025
Conference Call Time
7:00AM ET

Conference Call Resources

Xenetic Biosciences Earnings Headlines

Xenetic Biosciences (XBIO) Receives a Hold from H.C. Wainwright
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Xenetic Biosciences Inc
3XB0.SG,0P0001N0OC,0 (3XB0.SG)
See More Xenetic Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xenetic Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xenetic Biosciences and other key companies, straight to your email.

About Xenetic Biosciences

Xenetic Biosciences (NASDAQ:XBIO), Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

View Xenetic Biosciences Profile

More Earnings Resources from MarketBeat